絞り込み

16603

広告

解雇規制緩和という『ブラック・スワン』に備えよ (日経BP)

担当 さて、令和初のコラムのネタなんですけど……どうしましょうね。ってか、センセーはあんまり令和とか、そういうの気にしないでしょうけど。 鈴木 いや、そういうの...

  1. POLO試験の結果は進行膵癌の診療を変え...
  2. 万年研修医の覚悟がないと時代に取り残され...
  3. 認知症の睡眠問題は「診立て」が肝心 (日...
  4. 再製造医療機器流通のために病院が注意すべ...

ニュース一覧

The impact of Pompe disease on smooth muscle: a review.

著者 McCall AL , Salemi J , Bhanap P , Strickland LM , Elmallah MK
J Smooth Muscle Res.2018 ; 54(0):100-118.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (76view , 0users)

Full Text Sources

Miscellaneous

Pompe disease (OMIM 232300) is an autosomal recessive disorder caused by mutations in the gene encoding acid α-glucosidase (GAA) (EC 3.2.1.20), the enzyme responsible for hydrolyzing lysosomal glycogen. The primary cellular pathology is lysosomal glycogen accumulation in cardiac muscle, skeletal muscle, and motor neurons, which ultimately results in cardiorespiratory failure. However, the severity of pathology and its impact on clinical outcomes are poorly described in smooth muscle. The advent of enzyme replacement therapy (ERT) in 2006 has improved clinical outcomes in infantile-onset Pompe disease patients. Although ERT increases patient life expectancy and ventilator free survival, it is not entirely curative. Persistent motor neuron pathology and weakness of respiratory muscles, including airway smooth muscles, contribute to the need for mechanical ventilation by some patients on ERT. Some patients on ERT continue to experience life-threatening pathology to vascular smooth muscle, such as aneurysms or dissections within the aorta and cerebral arteries. Better characterization of the disease impact on smooth muscle will inform treatment development and help anticipate later complications. This review summarizes the published knowledge of smooth muscle pathology associated with Pompe disease in animal models and in patients.
PMID: 30787211 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード